Ability biologics is a technology company.
Ability biologics is a technology company.
Ability biologics has raised $18.0M across 1 funding round.
Ability biologics has raised $18.0M in total across 1 funding round.
Ability biologics has raised $18.0M in total across 1 funding round.
Ability biologics's investors include Amplitude VC, BDC Venture Capital.
Ability Biologics (also referred to as Ability Biotherapeutics) is a Montreal-based biotechnology company developing innovative, targeted immune-modulating biotherapeutics for cancer and autoimmune diseases.[1][2][3] It builds logic-gated antibodies using its proprietary AbiLeap™ platform, which integrates generative AI with a vast antibody-antigen database to create fully human, IgG-based antibodies that activate conditionally in specific microenvironments, offering superior selectivity, reduced toxicity, and broader therapeutic windows.[1][2][3][4] The company serves patients with unmet needs in immuno-oncology, solid tumors, and autoimmune disorders, addressing challenges like off-target effects in current therapies through four preclinical candidates, including pH-activated CD3 bispecific T-cell engagers and novel depletion strategies.[1][3][5] Emerging from stealth in late 2023 with $12 million in seed funding, Ability shows strong growth momentum, including a partnership with Mila (Quebec AI Institute) and plans to expand labs, triple staff by 2028, and advance to human proof-of-concept trials.[2][4][5]
Ability Biologics launched from stealth in December 2023, backed by Amplitude Ventures and co-founded by Giles Day (CEO) and Jean-Philippe Bürckert (VP of Technology), who assembled a team with deep expertise in immunology, antibody engineering, and drug development from bench to clinic.[2][4] The idea emerged from recognizing limitations in existing antibodies—lacking contextual precision—and leveraging AI to engineer "logic-enabled" versions that respond to disease-specific signals.[2][3] Early traction included closing a $12 million seed round to fuel preclinical work and unveiling the AbiLeap™ platform, built on over five years of curated antibody data.[2][4] Pivotal moments include a 2024 partnership with Mila for AI advancements and securing lab space at Inspire Bio Innovations in Montreal, positioning it for preclinical completion and clinical trials by 2026-2028.[4][5]
Ability rides the convergence of AI in drug discovery and precision immuno-oncology, where generative AI accelerates antibody design amid rising demand for safer immunotherapies post-checkpoint inhibitors.[2][4] Timing is ideal: AI-biotech funding rebounds, Quebec's life sciences hub (e.g., Inspire Bio) fosters collaboration, and unmet needs persist in solid tumors and autoimmunity despite market growth to $200B+ by 2030.[5] Favorable forces include vast proprietary data advantages over competitors and regulatory push for targeted therapies reducing side effects.[1][3] Ability influences the ecosystem by pioneering "contextually-gated" antibodies, potentially setting standards for AI-powered biotherapeutics and enabling partnerships for co-development.[2][4]
Ability is poised to advance its four candidates to IND-enabling studies and human trials within 2-3 years, leveraging lab expansions and AI partnerships to scale production and employee headcount threefold by 2028.[1][5] Trends like multimodal AI antibodies and microenvironment-responsive drugs will propel it, amid a biotech resurgence favoring platform companies with clinical traction. Its influence may evolve from preclinical innovator to a leader in selective immunotherapies, partnering with big pharma for global reach—transforming targeted treatments from promising to paradigm-shifting, much like its opening promise of "unparalleled specificity."[2][4]
Ability biologics has raised $18.0M across 1 funding round. Most recently, it raised $18.0M Seed in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $18.0M Seed | Amplitude VC, BDC Venture Capital |